Covering Up The Causes of Breast Cancer Since 1985: AstraZeneca's BCAM

Covering Up The Causes of Breast Cancer Since 1985: AstraZeneca's BCAM

Did you know that AstraZeneca, manufacturer of two blockbuster breast cancer drugs (one of which is classified as a known human carcinogen), is behind Breast Cancer Awareness Month?

Why is it, do you think, that during Breast Cancer Awareness Month (BCAM) you never hear the word "carcinogen" mentioned, but are barraged a million times over by the word "cure"?

Truth be told, BCAM should be renamed Breast Cancer Un-Awareness Month, as it has nothing to do with generating awareness about the true causes and solutions for the breast cancer epidemic and everything to do with making the public focus on a presumably not-yet-existent "cure" to be produced through the pharmaceutical pipeline somewhere off in the future only after enough money is raised. 

Instead of identifying and addressing the known causes of cancer, like the many mammary carcinogens now identified in body care products, GMO and processed foods, and our polluted environment, the mission of BCAM is to make people think that the best way to prevent breast cancer is to "detect it early."

And how?

By subjecting their breasts to radiation-based diagnostic screening that we now know actually causes breast cancer, and which has lead to over one million cases of falsely diagnosed and unnecessarily treated breast cancers in the past 30 years in U.S. women alone. One recent review on the topic of mammography concluded that they are harmful and should be avoided, and yet you will hear countless messages this month that breast screenings are safe and effective for reducing breast cancer mortality -- technically, a lie. 

This viral meme describes the underlying agenda succinctly:

Back in 2012, when we first wrote "The Dark Side of Breast Cancer [Un]Awareness Month," in order to shed light on this travesty, the real history of Breast Cancer Awareness Month's origins was still relatively unknown despite the fact that it was a matter of public record. According to the Wikipedia page on the topic:

"NBCAM was founded in 1985 as a partnership between the American Cancer Society and the pharmaceutical division of Imperial Chemical Industries (now part of AstraZeneca, maker of several anti-breast cancer drugs). The aim of the NBCAM from the start has been to promote mammography as the most effective weapon in the fight against breast cancer."  

The reference link listed on Wikipedia for the paragraph above comes from the BCAM website, but is now dead. For reasons that remain a mystery, the BCAM website was taken offline by AstraZeneca in the intervening years. Despite this, the BCAM domain name -- -- still links directly to AtraZeneca's HealthCare Foundation page; astounding evidence that AstraZeneca owned and controlled BCAM and still does. You can still view the WayBackMachine's archived NBCAM website here if you are curious.

And so why is this connection so important? 

What is so disturbing about AstraZeneca's founding role in BCAM is that it "just happens" to make two blockbuster breast cancer drugs, Tamoxifen and Arimidex -- a conflict of interest so flagrant, its hard to ignore. Even more disturbing is that Tamoxifen is actually classified by the International Agency for Research on Cancer as a known human carcinogen! A carcinogenic "treatment" for breast cancer?  No wonder BCAM won't allow the word "carcinogen" mentioned in any of its campaigns. 

Continue to Page 2

Pages :
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of GreenMedInfo or its staff.

Popular Threads

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2016, Journal Articles copyright of original owners, MeSH copyright NLM.